Switching first-line targeted therapy after not reaching low disease activity within 6&#xA0;months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

Rheumatoid Arthritis

Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study

Clin Rheumatol.

Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J

doi: 10.1007/s10067-017-3779-2.

Rheumatoid Arthritis

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

J Int Med Res.

Conigliaro P, Chimenti MS, Triggianese P, Ballanti E, Sunzini F, Duca I, Perricone R

doi: 10.1177/

Psoriatic Arthritis

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Rheumatology (Oxford).

Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ, Nantel F

doi: 10.1093/rheumatology/key359.

Rheumatoid Arthritis

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes

Ann Rheum Dis.

Paulshus Sundlisæter N, Aga AB, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA, ARCTIC study group

doi: 10.1136/annrheumdis-

Rheumatoid Arthritis

Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

Arthritis Res Ther

Jung SY, Koh JH, Kim KJ, Park YW, Yang HI, Choi SJ, Lee J, Choi CB, Kim WU

doi: 10.1186/s13075-021-02566-z

Rheumatoid Arthritis

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Ann Rheum Dis.

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM

doi: 10.1136/annrheumdis-2020-217209.

Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

Clin Rheumatol.

Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators

doi: 10.1007/s10067-017-3901-5.

Psoriatic Arthritis

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries

Ann Rheum Dis.

Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L

doi: 10.1136/annrheumdis-2018-214140.

Rheumatoid Arthritis

Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis

Arthritis Care Res (Hoboken)

Fleischmann R, Liu J, Zhu J, Segurado OG, Furst DE

doi: 10.1002/acr.24583

Dermatology · Immunology · Rheumatology

Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

Related content

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes

Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries

Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis